Praxis Precision Medicines, Inc. - 8-K Filing
Praxis Precision Medicines announced that the FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide targeting seizures in SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variants. This designation follows positive topline results from the EMBRAVE Part A trial, a Phase 1/2 study involving nine pediatric patients aged 2–12 years. (Items: 8.01 Other Events)
Tickers: $PRAX